Dengue is one of the fastest spreading mosquito-borne diseases on the planet and Derek Wallace from Takeda Pharmaceuticals is leading the fight against its spread.
Takeda’s Derek Wallace discussed the thorough process of developing the dengue vaccine, which they are calling TAK- 003. According to the New England Journal of Medicine, TAK- 003 is 80% effective in preventing people from getting dengue and 95% effective in preventing hospitalizations associated with dengue fever.Even though the company claims that the vaccine, TAK- 003, will bring about a major development in the fight against dengue, they still have a long way to go. Stephen Waterman, the head of US Centres for Disease Control and Prevention’s Dengue Branch, also got in talks with NPR and expressed that a full trial data of the study over a longer period of time is required to be sure of the vaccine’s efficacy rates. Waterman was also a part of the study conducted by Takeda. To be even more accurate, the company’s officials have decided to keep the study going by checking on the participants of TAK- 003’s development study for some more years, according to NPR reports.